-Reproterol_Structural_Formula_V1.svg) | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Inhalation (MDI),IV |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.053.579 |
| Chemical and physical data | |
| Formula | C18H23N5O5 |
| Molar mass | 389.412 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Reproterol is a short-acting[1]β2 adrenoreceptor agonist used in the treatment ofasthma.[2]
It was patented in 1965 and came into medical use in 1977.[3]
Reproterol contains a stereocenter and ischiral. There are thus twoenantiomers, the (R)-form and the (S)-form. The commercial preparations contain the drug as aracemate, an equal mixture of the two enantiomers.[4]
| Enantiomers of reproterol | |
|---|---|
-Reproterol_Structural_Formula_V1.svg) (R)-Reproterol CAS number: 210710-33-1 | -Reproterol_Structural_Formula_V1.svg) (S)-Reproterol CAS number: 210710-34-2 |
 | Thisdrug article relating to therespiratory system is astub. You can help Wikipedia byexpanding it. |